T-Cell Non-Hodgkin Lymphoma — Trials

T-Cell Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,008 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 225
Recruiting: 127
Ph III recruiting: 9
Growth YoY: +23.4%
Industry share: 21%
Top sponsor: Institute of Hematology & Blood Diseases Hospital, China
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (169)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04021082	CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)	withdrawn	Phase 2 / Phase 3	0	Portola PharmaceuticalsINDUSTRY	0	Feb 21, 2023	clinicaltrials
NCT01355783	A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma	withdrawn	Phase 3	0	Eisai Inc.INDUSTRY	1	Nov 18, 2013	clinicaltrials